Director buys 35,000 Lumexa Imaging (LMRI) shares in open-market trade
Filing Impact
Filing Sentiment
Form Type
4
Rhea-AI Filing Summary
Lumexa Imaging Holdings director Brett Brodnax reported an open-market purchase of 35,000 shares of Common Stock at $7.25 per share. Following this transaction, he directly owns 62,027 Lumexa Imaging Holdings shares, according to the Form 4 insider filing.
Positive
- None.
Negative
- None.
Insider Trade Summary
Net Buyer: 35,000 shares ($253,750)
Net Buy
1 txn
Insider
BRODNAX BRETT
Role
null
Bought
35,000 shs ($254K)
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Purchase | Common Stock | 35,000 | $7.25 | $254K |
Holdings After Transaction:
Common Stock — 62,027 shares (Direct, null)
Footnotes (1)
Key Figures
Shares purchased: 35,000 shares
Purchase price: $7.25 per share
Direct holdings after transaction: 62,027 shares
+1 more
4 metrics
Shares purchased
35,000 shares
Open-market Common Stock purchase on May 19, 2026
Purchase price
$7.25 per share
Price paid for LMRI Common Stock in the transaction
Direct holdings after transaction
62,027 shares
Total Common Stock directly owned by Brett Brodnax post-trade
Net buy shares
35,000 shares
Net buy direction in transaction summary for this Form 4
Key Terms
open-market purchase, Form 4, Common Stock, transaction code "P"
4 terms
open-market purchase financial
"transaction_action: "open-market purchase" for 35,000 Common Stock shares"
An open-market purchase is when an investor or a company buys shares on a public stock exchange at the going market price, rather than through a private deal. It matters to investors because these purchases change how many shares are available, can push the stock price up or signal confidence from large buyers, and often affect per-share metrics like earnings—think of it like someone buying lots of apples off a grocery shelf, reducing supply and potentially raising the price.
Form 4 regulatory
"INSIDER FILING DATA (Form 4) describes the reported transaction"
Form 4 is a official document that company insiders, such as executives or major shareholders, file with regulators whenever they buy or sell company shares. It provides transparency about how those with inside knowledge are trading, helping investors see if insiders are confident in the company's prospects or may be selling for personal reasons. This information can influence investor decisions by revealing insiders' perspectives on the company's value.
Common Stock financial
"security_title: "Common Stock" for the reported LMRI shares"
Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.
transaction code "P" regulatory
"transaction_code: "P", described as Purchase in open market"
FAQ
What insider transaction did Lumexa Imaging Holdings (LMRI) report?
Lumexa Imaging Holdings reported that director Brett Brodnax bought 35,000 shares of Common Stock in an open-market transaction. The Form 4 filing shows this purchase occurred on May 19, 2026, and was executed at a price of $7.25 per share.
What is Brett Brodnax’s total direct holding in LMRI after this trade?
After the reported transaction, Brett Brodnax directly owns 62,027 Lumexa Imaging shares. The Form 4 filing lists this figure as his total direct Common Stock holdings following the 35,000-share open-market purchase on May 19, 2026.
Was the LMRI insider transaction a purchase or a sale?
The LMRI insider transaction was a purchase. The Form 4 shows a transaction code “P,” described as an open-market or private purchase, with 35,000 Common Stock shares acquired by director Brett Brodnax at a price of $7.25 per share.
Does the LMRI Form 4 show any derivative or options activity?
The LMRI Form 4 does not show any derivative or option transactions. The derivative summary section is empty, and the only reported activity is a single non-derivative Common Stock open-market purchase by director Brett Brodnax on May 19, 2026.